Zevra Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Zevra Therapeutics has a total shareholder equity of $69.8M and total debt of $58.9M, which brings its debt-to-equity ratio to 84.4%. Its total assets and total liabilities are $191.6M and $121.8M respectively.
Key information
84.4%
Debt to equity ratio
US$58.90m
Debt
| Interest coverage ratio | n/a |
| Cash | US$89.38m |
| Equity | US$69.77m |
| Total liabilities | US$121.78m |
| Total assets | US$191.55m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1GDA's short term assets ($99.4M) exceed its short term liabilities ($34.5M).
Long Term Liabilities: 1GDA's short term assets ($99.4M) exceed its long term liabilities ($87.3M).
Debt to Equity History and Analysis
Debt Level: 1GDA has more cash than its total debt.
Reducing Debt: 1GDA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1GDA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1GDA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.